3. Soleno Therapeutics Inc. (NASDAQ: SLNO)
Soleno Therapeutics, Inc. (NASDAQ: SLNO) ranks third among the best cheap biotech stocks to buy now after delivering strong sales growth for its treatment VYKAT XR. The company focuses on developing therapies for rare metabolic and neurobehavioral disorders, particularly Prader-Willi syndrome.
Financial results for 2025 showed revenue of $91.7 million in the fourth quarter and $190.4 million for the full year from VYKAT XR sales. The company also achieved profitability with net income of $20.9 million and generated nearly $49 million in operating cash flow during the fourth quarter.
Analysts remain optimistic about Soleno’s long-term outlook. Wells Fargo maintained an Overweight rating, noting that the company’s valuation appears attractive relative to expected revenue growth in 2026. TD Cowen also reiterated a Buy rating while projecting continued expansion in patient adoption.
Click next to see the following stock...
